Welcome to our dedicated page for HeartBeam news (Ticker: BEAT), a resource for investors and traders seeking the latest updates and insights on HeartBeam stock.
HeartBeam, Inc. (Symbol: BEAT) is a cutting-edge medical technology company that focuses on developing and commercializing high-resolution ambulatory Electrocardiogram (ECG) solutions. These solutions are designed to detect and monitor cardiac diseases outside traditional healthcare settings, providing critical diagnostic capabilities in a more accessible manner.
HeartBeam's flagship product is an innovative, credit card-sized ECG device that is diagnostically equivalent to a cardiologist reading a patient's 12-lead ECG and examining the patient. This compact device integrates seamlessly with a cloud-based diagnostic expert system, offering a comprehensive and user-friendly solution for cardiac monitoring.
Notably, studies designed by Harvard Medical School faculty have demonstrated that HeartBeam's technology performs on par with, or better than, world-class cardiologists in diagnosing heart attacks. The system features personalized diagnostic thresholds and unique ECG markers that help pinpoint the location of a heart attack on a 3D heart model, enhancing the accuracy and depth of diagnostic information provided to healthcare professionals.
One of the key components of HeartBeam's technology is the iCardiologist application, which uses artificial intelligence and machine learning to continually improve its diagnostic accuracy and predictive capabilities. This application aids cardiologists by providing detailed patient analysis, thereby supporting more informed and timely medical decisions.
HeartBeam has developed a proprietary and patented Vector Electrocardiography (VECG) technology platform, which is the cornerstone of its high-resolution ECG solutions. The company has validated this platform and is in the process of seeking U.S. Food and Drug Administration (FDA) clearance for its initial telehealth products.
With its innovative approach and proven technology, HeartBeam is poised to make significant strides in the field of cardiac care, offering practical solutions that can be utilized outside traditional healthcare environments, thereby broadening access to critical diagnostic tools and improving patient outcomes.
Latest News: Source: HeartBeam, Inc.
- ------
- ------
- ------
HeartBeam, a medical technology company specializing in cardiac care, announced its addition to the Russell Microcap® Index. This inclusion is effective post-market close on June 28, 2024, following the FTSE Russell’s annual reconstitution, which ranks the 4,000 largest US stocks by market capitalization as of April 30. Being part of the Russell Microcap® Index, which lists the smallest 1,000 securities in the Russell 2000® Index plus the next 1,000 smallest eligible securities, provides HeartBeam with enhanced visibility and potential accessibility to $10.5 trillion in assets benchmarked against these indexes. The Russell indexes serve as key benchmarks for investment managers and institutional investors.
Epitel, a pioneer in AI-powered brain health solutions, has announced the appointment of Ken Nelson to its Board of Directors. Nelson, an expert in digital health and remote patient monitoring, brings over 20 years of experience to Epitel. He has held key positions in leading companies such as BioTelemetry, iRhythm, and Bardy Diagnostics, with notable achievements including BioTelemetry's $2.8 billion acquisition by Philips and Bardy Diagnostics' $450 million acquisition by HillRom/Baxter. As Epitel strives to revolutionize brain monitoring with AI and wearable EEG technology, Nelson's strategic insight is expected to drive the company's growth and commercial success. He currently holds influential positions in several MedTech startups and advisory boards.
HeartBeam (NASDAQ: BEAT) announced new study data showing that its AI algorithm combined with vectorcardiography (VCG) outperformed expert cardiologists in detecting atrial flutter, a common arrhythmia. The study, presented at the Heart Rhythm Society annual meeting, involved 173 VCGs, single-lead ECGs, and 12-lead ECGs. Key findings revealed a 40% improvement in detection sensitivity compared to single-lead ECGs reviewed by cardiologists and a 6% improvement over 12-lead ECGs. HeartBeam's core technology captures heart signals in three projections, aiming for a more personalized cardiac care approach. Their AIMIGo™ device, for patient use, is under FDA review.
HeartBeam, Inc. (NASDAQ: BEAT) has won the 'Best New ECG Technology Solution' award in the 8th annual MedTech Breakthrough Awards for their HeartBeam AIMIGo™ device. The AIMIGo™ device is a credit card-sized tool that allows for remote evaluation of cardiac symptoms, capturing heart signals in three projections and synthesizing them into a 12-lead ECG. The device is currently under FDA review and aims to provide a personalized approach to cardiac care outside of medical facilities.
HeartBeam, Inc. (NASDAQ: BEAT) reported positive results for its AIMIGo™ 3D VECG system, showcasing progress in clinical and regulatory milestones. The company anticipates FDA clearance by Q2 2024 for the AIMIGo system and plans for a launch by 2024 end. The VALID-ECG pivotal study for the 12-Lead Synthesis Software submission is underway, aiming to demonstrate similarity with a standard 12-lead ECG. HeartBeam AI showed improved performance in detecting arrhythmias, supported by new patents and positive data presented at EHRA conference. Cash and cash equivalents stood at approximately $12.6 million as of March 31, 2024, enabling future clinical and regulatory milestones.
FAQ
What does HeartBeam, Inc. do?
What is unique about HeartBeam's technology?
How does HeartBeam's iCardiologist application work?
What is VECG technology?
Has HeartBeam's technology been validated?
Is HeartBeam seeking FDA clearance?
What are the benefits of HeartBeam's ECG solutions?
Can HeartBeam's technology locate a heart attack?
How is HeartBeam improving cardiac care?
Where can I find the latest news on HeartBeam, Inc.?
